horiz_black-text_full-color_RED_CAMPP_edited_edited.png

The Center for Antiviral Medicines & Pandemic Preparedness (CAMPP) will draw upon world class drug discovery infrastructure embedded in an academic setting, as well as a network of expert virologists, chemists, pharmacologists, structural and computational biologists, and significant prior investments in global health drug discovery, to generate a more substantial pool of antiviral lead series and candidate drugs with the potential to address the immediate threat of SARS-CoV-2 and provide antiviral drug candidates that might quickly pivot to address future outbreaks or pandemics of other viruses of pandemic concern, including other coronaviruses, flaviviruses, and filoviruses.

AVIDD CAMPP Logos-01.png

Research Projects

The Center comprises six Projects that are supported by five Cores.

Project 1

Novel CoV Protease Inhibitors

Arnab Chatterjee | Calibr
Gaetano T. Montelione | Rensselaer Polytechnic Institute
Shaun Stauffer | Cleveland Clinic

Microscope
Image by Louis Reed

Project 2

Novel CoV Polymerase Inhibitors

Christopher F. Basler | Icahn School of Medicine at Mount Sinai
Gustavo Palacios | Icahn School of Medicine at Mount Sinai
Matthias Götte | University of Alberta
Christopher Parker | Scripps Research
Ben Cravatt | Scripps Research
Case McNamara | Calibr
Matthew Frieman | University of Maryland School of Medicine
Anil Gupta | Calibr

Project 3

Next-generation Antivirals Against
SARS-CoV-2 Druggable Proteins

Michael Farzan | Scripps Research
Sumit Chanda | Scripps Research
Suganya Selvarajah | Prosetta Biosciences
John Guatelli | University of California San Diego
Stanley Opella | University of California San Diego
Stuart Lipton | Scripps Research
Hyeryun Choe | Scripps Research

Image by CDC
Image by CDC

Project 4

Antivirals Against Undruggable SARS-CoV-2 Targets

Adolfo García-Sastre | Icahn School of Medicine at Mount Sinai
Sumit Chanda | Scripps Research
Matthew D. Disney | Scripps Research
Jose Gallego | Catholic University of Valencia
Hong Moulton | Oregon State University
Matthew J. Evans | Icahn School of Medicine at Mount Sinai
Beatriz Fontoura | UT Southwestern
Luis Martinez | University of Texas Medical Branch
Christopher Parker | Scripps Research
Ben Cravatt | Scripps Research

Project 5

Development of Antivirals to Flaviviruses

Sara Cherry | University of Pennsylvania
Sumit Chanda | Scripps Research
Michael S. Diamond | Washington University School of Medicine

Image by Егор Камелев
Image by CDC

Project 6

Development of Therapeutics
for Hemorrhagic Fever Viruses

Juan Carlos de la Torre | Scripps Research
Christopher F. Basler | Icahn School of Medicine at Mount Sinai
Jae Jung | Cleveland Clinic
Robert Davey | Boston University
Gaya Amarasinghe | Washington University School of Medicine
Christopher Parker | Scripps Research
Suganya Selvarajah | Prosetta Biosciences
Sumit Chanda | Scripps Research
Luis Martinez | University of Texas Medical Branch

Core A

High-throughput Screening Core

Kristen Johnson | Calibr

Pipetting Samples
Image by Chromatograph

Core B

Medicinal Chemistry Core

Anil Gupta | Calibr

Core C

Pharmacology & Formulation Core

Sean Joseph | Calibr
Victor Chi | Calibr

Scientist in the Lab
Image by Jaron Nix

Core D

Organoid & Animal Model Core

John Teijaro | Scripps Research
Matthew Frieman | University of Maryland School of Medicine
Jae Jung | Cleveland Clinic
Thomas Rogers | University of California San Diego
Kanta Subbarao | University of Melbourne

Core E

Structural Biology and Computational Modeling Core

Ian Wilson | Scripps Research
Andrew Ward | Scripps Research
Stefano Forli | Scripps Research

Image by Photoholgic
Petri Dish

Industry & Foundation Partners


Prosetta Biosciences
HitGen
Schrödinger
Johnson & Johnson
Intrepid Alliance
Gilead
Atomwise

Bill & Melinda Gates Foundation

Wellcome Trust